Colon Neoplasm Clinical Trial
Official title:
Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer
Colorectal cancer is a major health concern in the Western world with an estimated lifetime risk of 5-6%. The goal of achieving effective cancer prevention is driven by the prediction that CRC will become the leading cause of death (surpassing heart disease) in this decade, with an estimated 1,000,000 new cases and over 500,000 deaths per year, worldwide. Despite continuing advances in diagnosis and therapy, long-term survival rates have not improved significantly over the last four decades. Nearly 50% of all CRC patients will die of the disease. Preventive strategies offer the best hope, at least until our understanding of the biology of cancer matures to the point where it can be implemented into therapy. The search for new chemopreventive compounds with minimal toxicity raises particular interest in phytochemicals.Curcumin (diferuloylmethane) is a natural compound derived from the rhizome of Curcuma Longa, an East Indian plant, commonly called turmeric. It has been shown to possess potent anti-inflammatory and anti-oxidative properties, for which it has a long history of dietary use as a food additive. Curcumin has also a potent anti-proliferative effects against a variety of cancer cell lines in vitro, which stem from its ability to modulate many intracellular signal transduction pathways. Human phase I-II studies found curcumin to be safe, and indicated no dose-limiting toxicity when taken by mouth at doses up to 10 g/day. This data, together with the dismal therapeutic options available for colon cancer patients, suggest that curcumin warrants investigation in this setting. The present study evaluates gemcitabine in combination with curcumin and celecoxib for patients with colon cancer.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | March 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 3.1.1 Locally advanced or metastatic adenocarcinoma of the colon confirmed by histology or cytology. 3.1.2 Pateint who are qualified for treatment with gemcitabine 3.1.3 No prior chemotherapy for colon cancer. 3.1.4 Performance status 0-2 (ECOG scale). 3.1.5 Age = 18 y. 3.1.6 Adequate hematologic function (ANC = 1500/mm³, platelet count = 100,000/mm³ ). 3.1.7 Adequate hepatic function (total bilirubin = 2.0xUNL and AST, ALT and AP = 5.0xUNL) 3.1.8 adequate renal function (creatinine = 2.0). 3.1.9 Signed informed consent. Exclusion Criteria: 3.2.1 A history of treated or active central nervous system involvement by the tumor or active neurological disease. 3.2.2 Prior radiation. Patients with disease outside the irradiation field or documented disease progression of previously irradiated disease are eligible. 3.2.3 Unstable medical condition, including uncontrolled diabetes mellitus or hypertension, active infection, unstable CHF, uncontrolled arrhythmias or unstable coagulation disorders. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Tel-Aviv Sourasky Medical Center |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Terminated |
NCT04555135 -
A Clinical Study To Measure The Effect Of Use Of Artificial Intelligence (AI) Enabled Computer Aided Detection (CADe) Assistance Software In Detecting Colon Polyps During Standard Colonoscopy Procedures
|
N/A | |
Terminated |
NCT00249301 -
A Study of MLN8054 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT05279612 -
Effect Analysis of Neoadjuvant Chemoradiotherapy Combined With Surgery in Laparoscope for Advanced Colon Cancer
|
||
Active, not recruiting |
NCT04369053 -
Prevention of Colorectal Cancer Through Multiomics Blood Testing
|
||
Recruiting |
NCT05345613 -
Tranexamic Acid During Colonic Endoscopic Resection Procedures
|
Phase 4 | |
Recruiting |
NCT05411783 -
Low Tie Versus High Tie of the Inferior Mesenteric Vein During Colorectal Cancer Surgery: A Randomized Clinical Trial
|
N/A | |
Recruiting |
NCT03803891 -
Endoscopic Full-Thickness Resection In Colon
|
||
Completed |
NCT04799080 -
Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function
|
||
Recruiting |
NCT05034692 -
Application of Overlap Method to Digestive Tract Reconstruction of Totally Laparoscopic Left Colectomy
|
N/A | |
Recruiting |
NCT04920149 -
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
|
Phase 2 | |
Recruiting |
NCT03065257 -
Endoscopic Resection Multicenter Registry
|
N/A | |
Recruiting |
NCT03198338 -
Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit
|
N/A | |
Completed |
NCT05497726 -
Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW
|
N/A | |
Completed |
NCT03723720 -
Calculating of Correlations Between ADR, PDR, MAP
|
||
Completed |
NCT03730441 -
Correlation Between ADR of Screening and All Colonoscopies
|
||
Recruiting |
NCT05446558 -
Long-term Results in Intracorporeal Versus Extracorporeal Anastomosis in Laparoscopic Right Colectomy
|
N/A | |
Recruiting |
NCT03458689 -
Quadratus Lumborum Block Versus Transversus Abdominis Plane Block in Patients Undergoing Left Hemicolectomy
|
N/A | |
Completed |
NCT03719573 -
Geriatric Assessment and Intervention in Older Patients Undergoing Surgery for Colorectal Cancer
|
N/A | |
Completed |
NCT01535326 -
Comparing Water Immersion and Water Exchange Methods During Minimally Sedated Colonoscopy
|
N/A |